Hypersensitive C-reactive protein-atherogenic index (CAI) may serve as a novel marker for metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM). This evidence concerns the gene CRP and liver disorder.